Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Yannis Metaxas, Roger von Moos, Miklos Pless et al.|Annals of Oncology|2020Cited by 32
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trialYannis Metaxas, Roger von Moos, M. Frueh et al.|Annals of Oncology|2019Cited by 2